Joshua Zeidner, Professor of Medicine at the University of North Carolina at Chapel Hill, shared on X:
“We are entering a new frontier in AML.
The Paradigm study now out in NEJM showing improved EFS in younger non-fav. risk AML Tx with Aza/Ven vs. Intensive chemo.
Huge congrats to Amir Fathi and all authors for this incredibly important study and milestone.”
Title: Azacitidine–Venetoclax or Induction Chemotherapy for Acute Myeloid Leukemia
Authors: Amir T. Fathi, Alexander E. Perl, Geoffrey G. Fell, Brian A. Jonas, Brittany K. Ragon, Alice S. Mims, Uma Borate, Gabriel N. Mannis, Karen Quillen, Maximilian Stahl, Brandon J. Aubrey, Paul Koller, Andrew S. Artz, Monzr M. Al Malki, Anthony S. Stein, Guido Marcucci, Mary Linton B. Peters, Timothy A. Graubert, Peter Westervelt, Philip C. Amrein, Hanno R. Hock, Andrew M. Brunner, Gabriela Hobbs, Rupa Narayan, Michelle H. Lee, Peter G. Miller, Alyssa L. Watson, Richard Hao, Abigail C. Marola, Jennifer Lombardi-Story, Shilton Dhaver, Michael R. Grunwald, Yi-Bin Chen, Matthew J. Weinstock, Andrew H. Matthews, Ian McGovern, Brent L. Wood, Christopher S. Hourigan, Donna S. Neuberg, Areej El-Jawahri, Ibrahim Aldoss․
You can also read: Venetoclax + HMA in Newly Diagnosed AML: What Do Real-World Data Show?
